News


All series


All News

The review period for a&nbsp;supplemental new drug application for&nbsp;ruxolitinib has been extended by the FDA by 3 months, making the new action date May 24, 2019. The application is seeking the approval of the&nbsp;JAK1/JAK2&nbsp;inhibitor as a treatment for&nbsp;patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids.<br /> &nbsp;

Clinical researchers Dennis Slamon, MD, PhD, and Brian Druker, MD, were recently honored with the 2019 Sj&ouml;berg Prize for their ground-breaking contributions toward targeted therapy for patients with breast cancer and chronic myeloid leukemia, respectively.

A look back at all the&nbsp;FDA news&nbsp;in oncology from the month of&nbsp;January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.

Based on a recommendation from the FDA,&nbsp;Aveo Oncology has decided not to submit a new drug application for&nbsp;tivozanib. The FDA has advised it was not satisfied with&nbsp;the preliminary overall survival data from the phase III TIVO-3 trial of patients with highly refractory, advanced or metastatic renal cell carcinoma.

The American Society of Hematology has named Roy L. Silverstein, MD, as its 2019 president. He will serve a year-long term through the end of December 2019.